Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Offer to Shareholders

4 Mar 2015 07:00

RNS Number : 4613G
Angle PLC
04 March 2015
 



For immediate release

 4 March 2015

 

 

ANGLE plc

("ANGLE" or "the Company")

 

OFFER TO SHAREHOLDERS TO RAISE UP TO £1.5 MILLION

 

On 16 February 2015, ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, announced an issue of equity to raise £7.3 million (before expenses) by way of a Placing and Subscription. In conjunction with the Placing and Subscription, the Board also announced details of an Offer to Qualifying Participants to raise up to an additional £1.5 million (before expenses) through the issue of up to 2,307,692 New Ordinary Shares at an Issue Price of 65 pence per Ordinary Share.

 

The Company is pleased to announce that the Offer, which closed at 11.00 a.m. on 2 March 2015, was more than four times oversubscribed. The Offer raised the Offer Maximum of £1.5 million and, accordingly, 2,307,692 New Ordinary Shares have been issued. It is expected that Qualifying Participants that applied for the Offer will each receive approximately 21.75% of their applications.

 

Application has been made for 2,307,692 New Ordinary Shares to be admitted to trading on AIM. It is expected that admission to AIM will become effective on 10 March 2015.

 

Further details of the Placing, Subscription and Offer were set out in the announcement published by the Company on 16 February 2015.

 

Unless otherwise defined, capitalised terms shall have the same meaning as defined in the circular posted to Shareholders on 16 February 2015 (the "Circular"), which is available to view on the Company's website at www.angleplc.com.

 

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are delighted to have received such a strong level of support from our retail shareholders with the Offer more than four times over-subscribed. In total we have raised £8.2 million net of expenses in our Placing, Subscription and Offer, which puts ANGLE in a strong position to progress its first clinical application in ovarian cancer."

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Dr Christopher Golden (Nominated adviser)

Russell Kerr, Oliver Baxendale (Sales)  

 

020 7397 8900

Buchanan

Mark Court, Sophie Cowles, Jane Glover

020 7466 5000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEJJMJTMBTMTJA
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.